LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.73 -0.8

Buy Sell

Overview

Share price change

24h

Current

Min

3.62

Max

3.79

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+290.16% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	29M 257M
Previous open	4.53
Previous close	3.73

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 mar 2026, 18:34 UTC

Earnings

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19 mar 2026, 17:43 UTC

Major Market Movers

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19 mar 2026, 23:47 UTC

Earnings

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19 mar 2026, 23:39 UTC

Earnings

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19 mar 2026, 23:39 UTC

Earnings

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19 mar 2026, 23:39 UTC

Earnings

Li Ning: Outdoor Category Continued Growing >2331.HK

19 mar 2026, 23:38 UTC

Earnings

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19 mar 2026, 23:33 UTC

Market Talk

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

McCormick Has a Market Value of Around $14.8B -- WSJ

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19 mar 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19 mar 2026, 22:23 UTC

Market Talk

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19 mar 2026, 22:09 UTC

Market Talk

Major News Events

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19 mar 2026, 22:06 UTC

Market Talk

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19 mar 2026, 22:04 UTC

Earnings

Acquisitions, Mergers, Takeovers

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19 mar 2026, 22:03 UTC

Market Talk

Major News Events

Global Energy Roundup: Market Talk

19 mar 2026, 22:03 UTC

Market Talk

Major News Events

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19 mar 2026, 21:51 UTC

Earnings

Acquisitions, Mergers, Takeovers

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19 mar 2026, 20:57 UTC

Major News Events

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

19 mar 2026, 20:19 UTC

Major News Events

Brent Crude Retreats After Touching $119 -- WSJ

19 mar 2026, 19:49 UTC

Market Talk

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19 mar 2026, 19:26 UTC

Major News Events

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19 mar 2026, 19:10 UTC

Market Talk

Major News Events

Natural Gas Rises in Volatile Trading -- Market Talk

19 mar 2026, 19:06 UTC

Major News Events

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19 mar 2026, 18:08 UTC

Market Talk

Major News Events

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

290.16% upside

12 Months Forecast

Average 14.67 USD 290.16%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.